Risk of secondary cancers in women with breast cancer and the influence of radiotherapy: A national cohort study in Taiwan.

Breast cancer is the most common cancer in women worldwide; thus, the prolongation of survival, and the incidence and risk factors, including radiotherapy, for developing secondary malignancies are important. We compared the incidence of secondary and new primary cancers in women with breast cancer...

Descripción completa

Detalles Bibliográficos
Publicado en:Medicine Vol. 95; no. 49; pp. 1 - 8
Autores principales: Cheng-Yao Lin, Sih-Hao Chen, Chien-Cheng Huang, Shih-Feng Weng, Song-Tay Lee, How-Ran Guo, Shu-Chun Kuo, Shih-Bin Su, Lin, Cheng-Yao, Chen, Sih-Hao, Huang, Chien-Cheng, Weng, Shih-Feng, Lee, Song-Tay, Guo, How-Ran, Kuo, Shu-Chun, Su, Shih-Bin
Formato: research tables/charts Journal Article
Publicado: Lippincott Williams & Wilkins 12/6/2016
Acceso en línea:Ver este registro en EBSCOhost
Descripción
Sumario:Breast cancer is the most common cancer in women worldwide; thus, the prolongation of survival, and the incidence and risk factors, including radiotherapy, for developing secondary malignancies are important. We compared the incidence of secondary and new primary cancers in women with breast cancer (CA) and well-matched for age, geographic region, and monthly income cancer-free controls (CA). The risk for secondary cancers with and without radiotherapy was also compared in CA women. We enrolled 2422 CA patients and CA 12,110 controls. In a 4-year follow-up, the secondary cancers risk was significant in the CA group (adjusted hazard ratio [AHR]: 1.59; 95% confidence interval [CI]: 1.17-2.18). Only the risk of uterine cancer was significant compared with the controls (AHR: 6.30; 95% CI: 2.28-17.38). CA patients and <50 years old had a higher risk for secondary cancers. Developing secondary cancers was significant in the first follow-up year (AHR: 1.51; 95% CI: 1.11-2.06). Radiotherapy had no significant effect on the CA group, but it was significant (P = 0.0298) in women ≥60 years old (elderly). We recommend monitoring secondary cancers in CA women, especially those <50 years old, and during the first year of follow-up. Radiotherapy should be used more carefully in elderly CA women.